Cartilage repair scaffold and preparation method thereof

By using polymer mesh scaffolds and hydrogel-bound liposome microspheres in cartilage repair scaffolds, the problems of poor mechanical properties and shape fixation of cartilage repair scaffolds in the prior art are solved, and strength and biocompatibility are achieved The sexual enhancement is suitable for repairing a variety of cartilage lesions and reduces joint friction.

CN118697942BActive Publication Date: 2024-11-26BEIJING AKEC MEDICAL
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411201540.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-11-26
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

The existing cartilage repair stents lack the mechanical properties and viscoelasticity of natural cartilage, and have a large friction with joints and a fixed shape, making it difficult to meet the needs of cartilage lesions repair in different shapes and areas.

Method used

Using polymer mesh scaffolds as support carriers, filled with hydrogels and liposome microspheres. The polymer mesh scaffolds are made of lactide and trimethylene carbonate copolymers, and the hydrogels are made of silk fibroin and cross-sections. The combination agent is composed of liposome microspheres loaded with drugs, prepared by cross-linking reaction and lyophilization to form a cartilage repair scaffold with matching mechanical properties and biocompatibility.

Benefits of technology

The mechanical strength and biocompatibility of the cartilage repair stent is achieved, and the joint friction is reduced. It is suitable for Outerbridge grade III and IV lesions. It has adjustable shape and area, and the maximum repair area can reach 7cm2, reducing the damage to the patient's body. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118697942B_ABST
    Figure CN118697942B_ABST
Patent Text Reader

Abstract

The present invention provides a cartilage repair scaffold and a preparation method thereof, wherein the cartilage repair scaffold comprises a polymer mesh scaffold, the gaps of the polymer mesh scaffold are filled with hydrogel, and liposome microspheres are dispersed in the hydrogel, wherein the compression modulus of the polymer mesh scaffold is 7.5-9.5MPa. The cartilage repair scaffold uses the polymer mesh scaffold as a supporting carrier so that it has mechanical properties matching natural cartilage, and at the same time, the gaps of the polymer mesh scaffold are filled with hydrogel so that it has both good mechanical strength and good biocompatibility. In addition, liposome microspheres are also dispersed in the hydrogel, so that after being implanted in the body, the liposome microspheres are gradually degraded and slowly released under the action of body fluids to release liposomes, and the liposomes form a self-lubricating layer with the joint cavity fluid, which plays a role in reducing joint friction, and the shape and area of ​​the cartilage repair scaffold are adjustable, which can meet cartilage lesions of different shapes and areas.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of orthopedic implants, and in particular to a cartilage repair scaffold and a preparation method thereof. Background Art

[0002] Osteochondral lesions are common in clinical orthopedics. Most lesions do not heal on their own and may gradually develop into secondary osteoarthritis. Current repair materials for treating local cartilage defects (e.g., microfractures) lack the mechanical properties and viscoelasticity of natural cartilage.

[0003] Polylactic acid and its copolymers (such as polylactic acid-glycolic acid copolymer (PLGA)) are highly regarded biomedical polymer materials. They have excellent biodegradability and biocompatibility. Lactic acid is released during degradation, which is conducive to the growth of autologous cells and the repair and regeneration of tissues. They are a type of implant material with great development prospects for soft tissue repair and regeneration. Polylactic acid-based copolymers have the characteristics of high purity, good mechanical properties, and easy processing. However, implants made solely of polylactic acid materials have low initial strength, high brittleness, and poor cell affinity. It is difficult for cells to adhere, grow, and proliferate on them. Moreover, after degradation, these materials may become excessively acidic locally and may be accompanied by inflammation.

[0004] In view of this, the present invention is proposed. Summary of the invention

[0005] The main purpose of the present invention is to provide a cartilage repair scaffold and a preparation method thereof, so as to solve the technical problems in the prior art that the cartilage repair scaffold lacks the mechanical properties and viscoelasticity of natural cartilage, has a fixed shape, and has high friction with joints.

[0006] In order to achieve the above-mentioned purpose, according to one aspect of the present invention, a cartilage repair scaffold is provided, which comprises a polymer mesh scaffold, the gaps of the polymer mesh scaffold are filled with hydrogel, and liposome microspheres are dispersed in the hydrogel, wherein the compression modulus of the polymer mesh scaffold is 7.5-9.5MPa.

[0007] Furthermore, the polymer mesh stent is prepared from polymer monofilaments, and the raw materials of the polymer monofilaments are copolymers of lactide and trimethylene carbonate; further, the molar ratio of lactide to trimethylene carbonate is 2-4:1.

[0008] Furthermore, the raw materials of the hydrogel include a first degradable material and a cross-linking agent; wherein the first degradable material is silk fibroin, and the cross-linking agent is diglycidyl ether.

[0009] Furthermore, the hydrogel is loaded with a first drug, and the first drug includes at least one of chondroitin sulfate, diclofenac sodium, and glucosamine.

[0010] Furthermore, the raw materials of the liposome microspheres include dimyristoylphosphatidylcholine and / or hydrogenated soybean phosphatidylcholine.

[0011] Furthermore, the liposome microspheres are loaded with a second drug, which includes at least one of chondroitin sulfate, diclofenac sodium, glucosamine, and sodium hyaluronate.

[0012] Furthermore, the mass ratio of the hydrogel to the liposome microspheres is 1:0.4-0.8, and the mass ratio of the hydrogel to the polymer mesh scaffold is 2-1:1.

[0013] Furthermore, the particle size of the liposome microspheres is 50-100 nm.

[0014] Furthermore, the height of the cartilage repair scaffold is 1-2 cm.

[0015] Furthermore, the porosity of the hydrogel in the cartilage repair scaffold is 20-50%.

[0016] Furthermore, the pore size of the hydrogel in the cartilage repair scaffold is 10-30 μm.

[0017] Furthermore, the compression modulus of the cartilage repair scaffold is 7.5-9.5 MPa.

[0018] According to another aspect of the present invention, a method for preparing a cartilage repair scaffold is provided, and the preparation method comprises the following steps: step S1, dispersing silk fibroin in water to obtain a silk fibroin solution, mixing the silk fibroin solution, a cross-linking agent and liposome microspheres to obtain a mixed solution; step S2, providing a polymer mesh scaffold, immersing the polymer mesh scaffold in the mixed solution, and subjecting the mixed solution to a cross-linking reaction to obtain a composite scaffold; step S3: freeze-drying and sterilizing the composite scaffold in sequence to obtain a cartilage repair scaffold; wherein the liposome microspheres and the polymer mesh scaffold each independently have the same meaning as the first aspect above.

[0019] Further, step S1 comprises: the mass concentration of the silk fibroin solution is 8-12%;

[0020] and / or, dissolving liposomes in water to obtain liposome microspheres, wherein the raw materials of the liposomes include dimyristoylphosphatidylcholine and / or hydrogenated soybean phosphatidylcholine; further, the particle size of the liposome microspheres is 50-100 nm;

[0021] and / or, the cross-linking agent is diglycidyl ether;

[0022] And / or, the mass ratio of silk fibroin to liposome microspheres is 1:0.4-0.8.

[0023] Further, in step S2, the polymer mesh stent is woven from polymer monofilaments, and further, the polymer monofilaments are copolymerized from lactide and trimethylene carbonate;

[0024] and / or, the temperature of the cross-linking reaction is -20 to -10°C, and the time of the cross-linking reaction is 18 to 36 hours;

[0025] And / or, the mass ratio of silk fibroin to polymer mesh scaffold is 2-1:1.

[0026] Furthermore, step S3 includes: the sterilization treatment method is Co 60 sterilization.

[0027] By applying the technical solution of the present invention, the cartilage repair scaffold provided by the present application has mechanical properties matching those of natural cartilage by using a polymer mesh scaffold as a support carrier, and at the same time, hydrogel is filled in the gaps of the polymer mesh scaffold, so that it has both good mechanical strength and good biocompatibility. In addition, liposome microspheres are dispersed in the hydrogel, so that after being implanted in the body, the liposome microspheres are gradually degraded under the action of body fluids to slowly release liposomes, and the liposomes and the joint cavity fluid form a self-lubricating layer, which plays a role in reducing joint friction.

[0028] The cartilage repair scaffold provided in this application is suitable for Outerbridge grade III and IV lesions. The shape and area of ​​the cartilage repair scaffold are adjustable to meet the needs of cartilage lesions of different shapes and areas. The maximum repair area can reach 7cm 2 , solving the problem of limited repair area in the prior art. And the cartilage repair scaffold provided by the present application does not use the patient's own cartilage tissue as the raw material for cartilage repair, thus reducing the harm to the patient's body. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0030] Figure 1 A schematic diagram of the structure of a longitudinal stent woven with central axes of different diameters in some embodiments is shown.

[0031] FIG. 2( a ) is a schematic diagram showing a structural diagram of a method for weaving nodes of a polymer mesh stent in some embodiments.

[0032] FIG. 2( b ) shows a schematic structural diagram of a method for weaving nodes of a polymer mesh stent in some embodiments.

[0033] Figure 3 The tensile strength test curves of PLLA polymer monofilament and PTLA polymer monofilament in some embodiments are shown.

[0034] Figure 4 A schematic structural diagram of the polymer mesh stent in Example 1 is shown.

[0035] Figure 5 A compression strength test curve of the cartilage repair scaffold in Example 1 is shown.

[0036] Figure 6 The friction coefficient bar graphs of the cartilage repair scaffolds provided in Example 1 and Comparative Example 1 under different loading forces are shown.

[0037] The above drawings include the following reference numerals:

[0038] 1. First polymer tow; 2. Second polymer tow; 3. Third polymer tow; 4. Fourth polymer tow. DETAILED DESCRIPTION

[0039] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.

[0040] As analyzed in the background technology of this application, the cartilage repair scaffold in the prior art lacks the mechanical properties and viscoelasticity of natural cartilage, and has large friction with the joint and a fixed shape of the scaffold. In order to solve this problem, this application provides a cartilage repair scaffold and a preparation method thereof.

[0041] In a typical embodiment of the present application, a cartilage repair scaffold is provided, which includes a polymer mesh scaffold, the gaps of which are filled with hydrogel, and liposome microspheres are dispersed in the hydrogel, wherein the compression modulus of the polymer mesh scaffold is 7.5-9.5 MPa.

[0042] Hydrogel materials are an ideal cartilage repair scaffold material because of their high water content, good water retention, excellent biocompatibility, and appearance structure similar to the extracellular matrix, which can maintain the morphology of chondrocytes and the expression of cells related to chondrocyte functions. However, their mechanical strength is often poor. The present application combines hydrogel materials with polymer mesh scaffolds to make the performance of the two complement each other, thereby preparing a cartilage repair scaffold material with both mechanical strength and good biocompatibility.

[0043] The cartilage repair scaffold provided by the present application has mechanical properties matching those of natural cartilage by using a polymer mesh scaffold as a support carrier, and at the same time, hydrogel is filled in the gaps of the polymer mesh scaffold, so that it has both good mechanical strength and good biocompatibility. In addition, liposome microspheres are dispersed in the hydrogel, so that after being implanted in the body, the liposome microspheres are gradually degraded under the action of body fluids to slowly release liposomes, and the liposomes and the joint cavity fluid form a self-lubricating layer, which plays a role in reducing joint friction.

[0044] The cartilage repair scaffold provided in this application is suitable for Outerbridge grade III and IV lesions. The shape and area of ​​the cartilage repair scaffold are adjustable to meet the needs of cartilage lesions of different shapes and areas. The repair area can reach 7cm 2 , which solves the problem of limited repair area in the existing technology. And it does not use the patient's own cartilage tissue as the raw material for cartilage repair, which reduces the harm to the patient's body.

[0045] Typically but not limitatively, in the cartilage repair scaffold provided in the present application, the compression modulus of the polymer mesh scaffold is 7.5, 7.9, 8.1, 8.3, 8.5, 8.7, 8.9, 9.1, 9.3, 9.5 MPa or a range consisting of any two values.

[0046] In order to make the polymer mesh scaffold have mechanical properties matching those of natural cartilage, the polymer mesh scaffold is preferably woven from polymer filaments formed by polymer monofilaments. Since polylactic acid and its copolymers are biomedical polymer materials with high purity, good mechanical properties, and easy processing, in some preferred embodiments of the present application, the raw material of the polymer monofilament is a copolymer of lactide and trimethylene carbonate, so that the polymer mesh scaffold has excellent biocompatibility, biodegradability, and excellent mechanical properties, especially when the molar ratio of lactide to trimethylene carbonate is 2-4:1, it is more conducive to improving the mechanical properties of the polymer monofilament.

[0047] Typically, but not limiting, the molar ratio of lactide to trimethylene carbonate in the raw material of the polymer monofilament is 2:1, 2.5:1, 3:1, 3.5:1, 4:1 or a range consisting of any two of these numbers.

[0048] The specific type of the above hydrogel is not limited, and any hydrogel commonly used in the field of bone repair can be used. In order to further promote cell growth, the raw materials of the hydrogel preferably include a first degradable material and a cross-linking agent, wherein the first degradable material is silk fibroin and the cross-linking agent is diglycidyl ether.

[0049] There are many kinds of osteochondral lesions in clinical orthopedics. In order to better carry out targeted repair of different lesions and further reduce inflammation, in some embodiments of the present application, the hydrogel is loaded with a first drug, which includes but is not limited to one or more of chondroitin sulfate, diclofenac sodium, and glucosamine.

[0050] In the present application, the liposome microspheres can be degraded and slowly released under the action of body fluids, and the liposomes can form a self-lubricating layer with the joint cavity fluid, thereby reducing joint friction. In order to further improve the self-lubricating effect of the above-mentioned cartilage repair scaffold, it is preferred that the raw materials of the above-mentioned liposome microspheres include dimyristoylphosphatidylcholine (DMPC) and / or hydrogenated soybean phosphatidylcholine (HSPC).

[0051] In some embodiments, in order to more advantageously promote the repair of lesions, the liposome microspheres are preferably loaded with a second drug, which includes at least one of chondroitin sulfate, diclofenac sodium, glucosamine, and sodium hyaluronate.

[0052] In the cartilage repair scaffold provided by the present application, the hydrogel in the gap of the polymer mesh scaffold is loaded with liposome microspheres. After the cartilage repair scaffold is implanted, the liposome microspheres dispersed in the hydrogel are further slowly released, and the released liposomes play a role in lubrication and reducing joint friction. In order to further improve the self-lubricating effect of the cartilage repair scaffold, the mass ratio of the hydrogel to the liposome microspheres is preferably 1:0.4-0.8.

[0053] In order to further improve the mechanical strength and biocompatibility of the cartilage repair scaffold material, the mass ratio of the hydrogel to the polymer mesh scaffold is preferably 2-1:1.

[0054] Typically but not limiting, in the cartilage repair scaffold, the mass ratio of hydrogel to liposome microspheres is 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8 or a range consisting of any two values. The mass ratio of hydrogel to polymer mesh scaffold is 2:1, 1.8:1, 1.5:1, 1.4:1, 1.2:1, 1:1 or a range consisting of any two values.

[0055] In some specific embodiments, the height of the cartilage repair scaffold is preferably 1-2 cm, so that it can be adjusted according to the height of the repair position to meet the needs of different repair positions and repair areas.

[0056] In other specific embodiments, the porosity of the hydrogel in the cartilage repair scaffold is preferably 20-50%, and the pore size of the hydrogel in the cartilage repair scaffold is preferably 10-30 μm, so as to facilitate filling an appropriate amount of hydrogel in the gaps of the polymer mesh scaffold and further improve the biocompatibility of the cartilage repair scaffold. In addition, under the condition of unchanged cross-linking reaction conditions and freeze-drying temperature, the pore size and porosity of the hydrogel are mainly determined by the concentration of silk fibroin in the mixed solution.

[0057] In order to further promote the matching of the mechanical properties of the cartilage repair scaffold with those of natural cartilage, the compression modulus of the cartilage repair scaffold is preferably 7.5-9.5 MPa.

[0058] In a second typical embodiment of the present application, a method for preparing a cartilage repair scaffold is also provided, and the preparation method comprises the following steps: step S1, dispersing silk fibroin in water to obtain a silk fibroin solution, mixing the silk fibroin solution, a cross-linking agent and liposome microspheres to obtain a mixed solution; step S2, providing a polymer mesh scaffold, immersing the polymer mesh scaffold in the mixed solution, and subjecting the mixed solution to a cross-linking reaction to obtain a composite scaffold; step S3: freeze-drying and sterilizing the composite scaffold in sequence to obtain a cartilage repair scaffold; wherein, the liposome microspheres and the polymer mesh scaffold have the same meaning as in the first typical embodiment, and will not be repeated here.

[0059] The cartilage repair scaffold provided in the present application is prepared by first immersing a polymer mesh scaffold into a mixed solution, and then subjecting the mixed solution to a cross-linking reaction. Silk fibroin is cross-linked to form a hydrogel that fills the gaps in the polymer mesh scaffold, and liposome microspheres are dispersed in the hydrogel. The operation is simple and convenient, the raw material ratio is easy to control and adjust, and industrial production can be realized.

[0060] In order to further improve biocompatibility and promote cell growth, preferably in step S1: the mass concentration of the silk fibroin solution is 8-12%, such as 8%, 9%, 10%, 11%, 12% or a range consisting of any two values.

[0061] In some embodiments, the silk fibroin solution is prepared by the following steps: placing the silk cocoons in a sodium bicarbonate solution and boiling them, then washing them with ultrapure water for several times, drying them to obtain silk fibroin, then dissolving the silk fibroin in an aqueous solution of lithium bromide, dialyzing them to remove bromide ions and lithium ions, then removing insoluble impurities by solid-liquid separation, and finally concentrating them to obtain a silk fibroin solution with a mass concentration of 8-12%. Preferably, PEG (polyethylene glycol) with a mass concentration of 30% is used for the concentration.

[0062] For example, in the aqueous solution of lithium bromide, the molar concentration of lithium bromide is 9-10 mol / L, preferably 9.3 mol / L. The solid-liquid separation is preferably centrifugal, and more preferably the centrifugal speed is 10000-12000 rpm, and the centrifugal time is 5-20 min.

[0063] In other embodiments, liposome microspheres are prepared according to the following steps: dispersing the liposome raw material in water to obtain a liposome solution, ultrasonically treating the liposome solution to obtain a liposome microsphere solution, passing the liposome microsphere solution through a polymer membrane to screen the particle size, and then freeze-drying to obtain liposome microspheres.

[0064] For example, liposome microspheres are prepared according to the following steps: the liposome raw material (dimyristoyl phosphatidylcholine and / or hydrogenated soybean phosphatidylcholine) is dispersed in water to obtain a liposome solution, and after ultrasonic treatment for 10-20 minutes, the liposomes form liposome microspheres and are dispersed in water to obtain a liposome microsphere solution. The liposome microsphere solution is sequentially passed through 400nm, 200nm and 100nm polycarbonate membranes under argon pressure to reduce the size of the liposome microspheres to obtain liposome microspheres with a particle size of ≤100nm. Finally, the liposome microspheres are freeze-dried at -50°C and stored at 2-8°C for subsequent use.

[0065] In the above step S2, the polymer mesh stent can be woven from polymer filaments formed by polymer monofilaments, or can be 3D printed from polymer monofilaments. Preferably, the polymer mesh stent is woven from filaments. The specific weaving method is not limited, and any commonly used weaving method in the art can be used, including but not limited to twist weaving, weft knitting, diamond weaving, three-way weaving, etc.

[0066] In a specific embodiment, the polymer mesh stent is woven in the following manner:

[0067] (1) Providing multiple central shafts with different diameters, and weaving polymer filaments around the central shafts by diamond weaving to form longitudinal stents with different diameters, such as Figure 1 As shown; wherein the polymer tow is formed by twisting and weaving polymer monofilaments;

[0068] (2) nesting longitudinal stents of different diameters layer by layer according to their diameters to form multi-layer nested longitudinal stents, wherein the diameters of the multi-layer nested longitudinal stents increase from the inside to the outside;

[0069] (3) The mesh intersections of the multi-layer nested longitudinal stents are used as fixed points, and then the fixed points of each layer of longitudinal stents are transversely braided and connected from the outside to the inside using a polymer tow similar to the three-way braiding method. After the braiding is completed, annealing is performed to obtain a polymer mesh stent. The braiding method at the nodes of the polymer mesh stent is shown in Figures 2 (a) and 2 (b).

[0070] As can be seen from FIG. 2 (a) and FIG. 2 (b), the polymer mesh stent is woven by four different polymer bundles, and the weaving methods at different fixed points can be the same or different. The first polymer bundle 1, the second polymer bundle 2, the third polymer bundle 3 and the fourth polymer bundle 4 are woven in different ways at the fixed points to further improve the compressive strength of the polymer mesh stent.

[0071] It should be noted that the first polymer filament bundle 1, the second polymer filament bundle 2, the third polymer filament bundle 3 and the fourth polymer filament bundle 4 are each independently made of polymer monofilaments to further increase the mechanical strength of the polymer mesh support. Preferably, the diameters of the first polymer filament bundle 1, the second polymer filament bundle 2, the third polymer filament bundle 3 and the fourth polymer filament bundle 4 are each independently 0.4-1 mm.

[0072] In some embodiments, the polymer monofilament is obtained according to the following steps: lactide and trimethylene carbonate are copolymerized under vacuum conditions with propylene glycol as an initiator and stannous octoate as a catalyst to obtain a polymer crude product, preferably the molar ratio of lactide to trimethylene carbonate is 2-4:1. The polymer crude product is first dissolved in dichloromethane, and then placed in ethanol for precipitation to obtain a polylactide and trimethylene carbonate copolymer (PTLA), which is then dried for use. The PTLA prepared above is melt-extruded through an extruder, cooled and shaped, and then stretched through a heating box to further increase the tensile strength of the polymer monofilament to obtain a PTLA polymer monofilament, preferably the PTLA polymer monofilament has a diameter of 0.20-0.30 mm.

[0073] For example, in the copolymerization reaction, the mass ratio of the sum of lactide and trimethylene carbonate to propylene glycol is preferably 1:0.003-0.006, the molar ratio of the sum of lactide and trimethylene carbonate to stannous octoate is preferably 2000:1, the copolymerization reaction temperature is preferably 120-160° C., and the copolymerization reaction time is 36-96 h.

[0074] In some specific embodiments, the polymer monofilament is prepared by the following steps: PTLA is melt-extruded through a single screw extruder, the temperature of the extruder is set to 190° C., and the temperature of the extruder head is set to 240° C. After extrusion, it is placed in a water bath at 25° C. for shaping treatment, and the shaped polymer monofilament is collected. The shaped polymer monofilament is heated to 110-140° C. in a heating and stretching device and then stretched, preferably with a stretching ratio of 4-8, to obtain a PTLA polymer monofilament with a diameter of 0.20-0.30 mm.

[0075] Because the hose repair stent must not only have a certain support force but also a certain toughness when implanted in the body to further ensure that the stent undergoes a certain deformation during the extrusion and expansion process. The tensile strength of polylactide (PLLA) polymer monofilament (diameter 0.22mm) and PTLA polymer monofilament (diameter 0.22mm) were tested at room temperature. The results are as follows Figure 3 As shown. Figure 3 It can be seen that compared with polylactide (PLLA) polymer monofilaments, PTLA polymer monofilaments obtained by copolymerization of lactide and trimethylene carbonate have stronger toughness. Therefore, in order to further improve the toughness of the cartilage repair scaffold, the preferred polymer monofilament is PTLA polymer monofilament.

[0076] In addition, in order to further improve the mechanical strength of the PTLA polymer monofilament, the PTLA polymer monofilament is preferably annealed. Table 1 shows the test data of the number average molecular weight, weight average molecular weight, tensile strength, elongation at break and Young's modulus of the PTLA polymer monofilament before and after annealing. It can be seen from Table 1 that the annealing further improves the mechanical strength and Young's modulus of PTLA. In order to simplify the annealing process, the polymer mesh scaffold is preferably annealed after weaving to further improve its mechanical strength and modulus. The annealing temperature after weaving is preferably 100-120°C (such as 100, 105, 110, 120°C, etc.), and the annealing time is preferably 0.5-2h (such as 0.5, 1, 1.5, 2h, etc.).

[0077] Table 1

[0078]

[0079] In some embodiments, the mixed solution containing silk fibroin undergoes a cross-linking reaction at low temperature. The low temperature treatment method further avoids the problem of high temperature ineffectiveness of the drug when the hydrogel is loaded with the first drug. Preferably, the temperature for the cross-linking reaction is -20 to -10°C, and the time for the cross-linking reaction is 18-36h.

[0080] In some specific embodiments, the cartilage repair scaffold is prepared by the following steps: the silk fibroin solution, the cross-linking agent, and the liposome microspheres are mixed at a stirring speed of 300 rpm for 30 minutes to make the raw materials evenly mixed to obtain a mixed solution. Then the polymer mesh scaffold is immersed in the mixed solution and ultrasonically vibrated for 30 minutes to further promote the removal of bubbles so that the hydrogel formed by cross-linking can be more fully immersed in the fine gaps of the polymer mesh scaffold. Subsequently, the low-temperature cross-linking treatment is carried out at a temperature of -15°C for 24 hours to further promote the cross-linking of the hydrogel, and to promote its suspension on the polymer mesh scaffold and fully fill the gaps in the polymer mesh scaffold to obtain a composite scaffold. The composite scaffold is then freeze-dried at -50°C for 24 hours, and the cartilage repair scaffold is obtained after sterilization.

[0081] Exemplarily, the preferred crosslinking agent is diglycidyl ether.

[0082] In addition, during the preparation of the cartilage repair scaffold, in order to further improve the self-lubricating properties and biocompatibility of the cartilage repair scaffold, the mass ratio of silk fibroin to liposome microspheres is preferably 1:0.4-0.8.

[0083] In order to make the cartilage repair scaffold have both good mechanical properties and biocompatibility, the mass ratio of silk fibroin to polymer mesh scaffold is preferably 2-1:1.

[0084] Typically but not limiting, in the cartilage repair scaffold, the mass ratio of silk fibroin to liposome microspheres is 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8 or a range consisting of any two values. The mass ratio of silk fibroin to polymer mesh scaffold is 2:1, 1.8:1, 1.5:1, 1.4:1, 1.2:1, 1:1 or a range consisting of any two values.

[0085] In the present application, the specific method of sterilization is not limited. From the perspective of cost saving, the preferred sterilization treatment method is Co60 sterilization.

[0086] The beneficial effects of the present application will be further illustrated below in combination with embodiments and comparative examples.

[0087] Example 1

[0088] The cartilage repair scaffold provided in this embodiment is prepared according to the following steps:

[0089] (1) Preparation of a mixed solution of silk fibroin solution, crosslinking agent and liposome microspheres

[0090] (1.1) Preparation of silk fibroin solution:

[0091] The silkworm cocoons were placed in a sodium bicarbonate solution with a mass fraction of 0.5% and boiled twice, each time for 30 minutes. After boiling, they were washed with ultrapure water for 5 times and dried to obtain silk fibroin. The silk fibroin was dissolved in a 9.3 mol / L lithium bromide aqueous solution and dialyzed, wherein the mass ratio of silk fibroin to lithium bromide aqueous solution was 2:25. Then, the silk fibroin solution was obtained by centrifugation at a centrifugal speed of 12000 rpm for 10 minutes and filtration to remove insoluble impurities. Finally, the silk fibroin solution was concentrated by a PEG (polyethylene glycol) solution with a mass fraction of 30% to obtain a silk fibroin solution with a mass fraction of 10%.

[0092] (1.2) Preparation of liposome microspheres:

[0093] Hydrogenated soybean phosphatidylcholine (HSPC) was dispersed in water and ultrasonically treated at 60°C for 15 minutes to obtain a hydrogenated soybean phosphatidylcholine microsphere solution. The hydrogenated soybean phosphatidylcholine microsphere solution was then passed through 400nm, 200nm and 100nm polycarbonate membranes in sequence under argon pressure, and then freeze-dried at -50°C to obtain hydrogenated soybean phosphatidylcholine microspheres with a size of ≤100nm.

[0094] (1.3) Preparation of mixed solution:

[0095] Diglycidyl ether and hydrogenated soybean phosphatidylcholine microspheres were added to the silk fibroin solution (10wt%), and the mixture was stirred at a rotation speed of 300 rpm for 30 minutes to obtain a mixed solution after being fully mixed. The mass ratio of silk fibroin to diglycidyl ether was 1:0.2, and the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres was 1:0.6.

[0096] (2) Preparation of polymer mesh scaffolds

[0097] (2.1) Preparation of polymer monofilaments:

[0098] Lactide, propylene glycol, stannous octoate and trimethylene carbonate were added to the reactor in sequence, and copolymerization occurred under vacuum environment, reaction temperature of 140°C and reaction time of 72h to obtain a crude polymer product. The molar ratio of lactide to trimethylene carbonate was 3:1, the mass ratio of the total amount of lactide and trimethylene carbonate to propylene glycol was 1:0.005, and the molar ratio of the total amount of lactide and trimethylene carbonate to stannous octoate was 2000:1. The crude copolymer was first dissolved in dichloromethane and then placed in ethanol for precipitation to obtain a polylactide and trimethylene carbonate copolymer (PTLA), which was dried for later use.

[0099] Subsequently, PTLA was melt-extruded through a single-screw extruder, the temperature of the extruder was set to 190°C, and the temperature of the extrusion head was set to 240°C. After extrusion, it was placed in a 25°C water bath for shaping, and the shaped monofilaments were collected. The shaped monofilaments were stretched in a heating box at a temperature of 120°C, with a stretch ratio of 6, to obtain PTLA polymer monofilaments.

[0100] (2.2) Preparation of polymer mesh scaffolds:

[0101] Polymer filaments are woven into Figure 4 The polymer mesh stent shown has a compression modulus of 8.5 MPa, wherein the polymer filament bundles are twisted and woven from the polymer monofilaments prepared in step (2.1).

[0102] (3) Preparation of cartilage repair scaffold

[0103] The polymer mesh scaffold was immersed in a mixed solution, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution was 1.5:1, ultrasonically vibrated for 30 minutes, and then cross-linked at -15°C for 24 hours to obtain a composite scaffold. The composite scaffold was freeze-dried at -50°C for 24 hours and sterilized with Co60 to obtain a cartilage repair scaffold with a height of 1 cm.

[0104] Example 2

[0105] The difference from Example 1 is that in the process of weaving the polymer mesh stent in step (2.2), Example 2 changes the weaving method of the polymer mesh stent so that the compression modulus of the polymer mesh stent is 7.5 MPa. The rest is the same as Example 1 and will not be repeated here.

[0106] Example 3

[0107] The difference from Example 1 is that in Example 3, during the process of preparing the polymer mesh stent in step (2.2), the weaving method of the polymer mesh stent is changed so that the compression modulus of the polymer mesh stent is 9.5 MPa. The rest is the same as Example 1 and will not be repeated here.

[0108] Example 4

[0109] The difference from Example 1 is that in Example 4, during the process of preparing the polymer mesh stent in step (2.2), the weaving method of the polymer mesh stent is changed so that the compression modulus of the polymer mesh stent is 8 MPa. The rest is the same as Example 1 and will not be repeated here.

[0110] Example 5

[0111] The difference from Example 1 is that in Example 5, during the process of preparing the polymer mesh stent in step (2.2), the weaving method of the polymer mesh stent is changed so that the compression modulus of the polymer mesh stent is 9 MPa. The rest is the same as Example 1 and will not be repeated here.

[0112] Example 6

[0113] The difference from Example 1 is that in step (1.3) of Example 6, the amount of hydrogenated soybean phosphatidylcholine microspheres is adjusted so that the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres is 1:0.1. The rest is the same as Example 1 and will not be repeated here.

[0114] Example 7

[0115] The difference from Example 1 is that in step (1.3) of Example 7, the amount of hydrogenated soybean phosphatidylcholine microspheres is adjusted so that the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres is 1:0.4. The rest is the same as Example 1 and will not be repeated here.

[0116] Example 8

[0117] The difference from Example 1 is that in step (1.3) of Example 8, the amount of hydrogenated soybean phosphatidylcholine microspheres is adjusted so that the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres is 1:0.8. The rest is the same as Example 1 and will not be repeated here.

[0118] Example 9

[0119] The difference from Example 1 is that in step (1.3) of Example 9, the amount of hydrogenated soybean phosphatidylcholine microspheres is adjusted so that the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres is 1:1.2. The rest is the same as Example 1 and will not be repeated here.

[0120] Example 10

[0121] The difference from Example 1 is that in step (3) of Example 10, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution is adjusted to 0.5:1, and the rest is the same as Example 1 and will not be repeated here.

[0122] Embodiment 11

[0123] The difference from Example 1 is that in step (3) of Example 11, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution is adjusted to 1:1, and the rest is the same as Example 1 and will not be repeated here.

[0124] Example 12

[0125] The difference from Example 1 is that in step (3) of Example 12, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution is adjusted to 1.8:1, and the rest is the same as Example 1 and will not be repeated here.

[0126] Embodiment 13

[0127] The difference from Example 1 is that in step (3) of Example 13, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution is adjusted to 2:1, and the rest is the same as Example 1 and will not be repeated here.

[0128] Embodiment 14

[0129] The difference from Example 1 is that in step (3) of Example 14, the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution is adjusted to 3:1, and the rest is the same as Example 1 and will not be repeated here.

[0130] Comparative Example 1

[0131] The difference from Example 1 is that, in the step (1.3) of preparing the mixed solution in Comparative Example 1, no hydrogenated soybean phosphatidylcholine microspheres are added. The rest is the same as Example 1 and will not be described again.

[0132] Comparative Example 2

[0133] The difference from Example 1 is that in the process of preparing the polymer mesh stent in step (2.2), the weaving method of the polymer mesh stent is changed so that the compression modulus of the polymer mesh stent is 3 MPa. The other parts are the same as those in Example 1 and will not be repeated here.

[0134] Comparative Example 3

[0135] The difference from Example 1 is that in the process of preparing the polymer mesh stent in step (2.2), the weaving method of the polymer mesh stent is changed so that the compression modulus of the polymer mesh stent is 13 MPa. The other parts are the same as those in Example 1 and will not be repeated here.

[0136] Test Example 1

[0137] The compression modulus of the cartilage repair scaffolds provided in the above embodiments and comparative examples were tested respectively, and the results are shown in Table 2 below:

[0138] The compression modulus test method is as follows: statically compress the stent at a compression rate of 2 mm / min until the deformation reaches 50%.

[0139] Table 2

[0140]

[0141] in, Figure 5 The cartilage repair scaffold compression strength test curve provided in Example 1 is as follows: Figure 5 It can be seen that gradually increasing the pressure causes the cartilage repair scaffold to deform. When the pressure increases to 7.5-9.3 MPa, the deformation of the cartilage repair scaffold is 22-25%, and the scaffold will not be damaged. After the external force is removed, it can rebound to its original shape. Therefore, the cartilage repair scaffold provided by the present application has high-strength mechanical properties.

[0142] It can be seen from Examples 1-5 and Comparative Examples 2-3 that the compression modulus of the cartilage repair scaffold is similar to that of the polymer mesh scaffold, that is, by changing the pore size, porosity, weaving method or polymer filament diameter of the polymer mesh scaffold, the compression modulus of the polymer mesh scaffold is finally changed to obtain a cartilage repair scaffold with the desired compression modulus. Therefore, compared with Comparative Examples 2 and 3, in order to make the cartilage repair scaffold have mechanical properties that match natural cartilage, the compression modulus of the polymer mesh scaffold in this application is 7.5-9.5MPa (see the experimental results of Examples 1-5).

[0143] Test Example 2

[0144] The compression modulus and sliding friction coefficient of the cartilage repair scaffolds provided in the above-mentioned embodiments and comparative examples under different loading forces were measured respectively, and the results are shown in Table 3.

[0145] Among them, the testing method of the sliding friction coefficient is: polytetrafluoroethylene indenter (radius size is 2.5mm), sliding length is 5mm, sliding frequency is 1Hz, and the average sliding friction coefficient of 500 reciprocating cycles under different normal loading forces is tested at room temperature.

[0146] Table 3

[0147]

[0148] in, Figure 6 The friction coefficient bar graphs of the cartilage repair scaffolds provided in Example 1 and Comparative Example 1 under 2N, 5N, 10N, 20N, and 25N, respectively. The wavy shape above the column indicates that the scaffold has no sliding ability under the loading force, and the symbol I above the column indicates that the scaffold has sliding ability under the loading force. Figure 6 It can be seen that when the loading force increases to 10 N without liposome microspheres, the cartilage repair scaffold has no sliding ability, while when the loading force increases to 25 N, the cartilage repair scaffold still has sliding ability. The addition of liposome microspheres significantly reduces the friction coefficient of the cartilage repair scaffold, which indicates that the cartilage repair scaffold has a good joint lubrication effect when implanted in the body.

[0149] In comparative example 1, hydrogenated soybean phosphatidylcholine microspheres are not added when preparing the mixed solution, and the average sliding friction coefficient is large, and when the loading force is 10N, the cartilage repair scaffold does not have the ability to slide. When a small amount of hydrogenated soybean phosphatidylcholine microspheres are added to the mixed solution, that is, the mass ratio of silk fibroin to hydrogenated soybean phosphatidylcholine microspheres in Example 6 is 1:0.1, the average sliding friction coefficient is significantly reduced, and the cartilage repair scaffold still has the ability to slide even if the loading force is increased to 25N. It shows that the liposome microspheres play a role in promoting the self-lubrication of the cartilage repair scaffold. Compared with Example 6, the mass ratio of hydrogenated soybean phosphatidylcholine microspheres in Example 1 and Examples 7-9 increases, and the average sliding friction coefficient is significantly reduced by more than 5 times. When the loading force increases from 2N to 25N, the average sliding friction coefficient remains almost unchanged, indicating that when the mass ratio of hydrogenated soybean phosphatidylcholine microspheres to silk fibroin increases to more than 0.4, the self-lubricating effect of the cartilage repair scaffold is more excellent.

[0150] Test Example 3

[0151] The pore size and porosity of the hydrogel in the cartilage repair scaffolds provided in the above examples and comparative examples were measured respectively, and the cytotoxicity of the cartilage repair scaffolds was tested by MTT method. The results are shown in Table 4.

[0152] Among them, the MTT cytotoxicity test method is: L929 cells are used to test the 100% extract of the cartilage repair scaffold, and the absorbance value (OD test value) at 570nm after 24 hours of testing culture is calculated to obtain the cell survival rate (%) = (OD test value / OD blank value) * 100%. Among them, the 100% extract is MEM culture medium (Beijing Ita Biotechnology Co., Ltd.), and the OD blank value is the absorbance value of the 100% extract at 570nm after 24 hours of L929 cell test culture. If the cell survival rate is low, the cytotoxicity of the cartilage repair scaffold is high and the biocompatibility of the cartilage repair scaffold is poor.

[0153] The pore size and porosity testing methods are as follows: SEM is used to observe the morphology of the cross section of the scaffold, and Image-J three-dimensional analysis software is used to analyze the pore size and porosity.

[0154] Table 4

[0155]

[0156] Compared with the mass ratio of silk fibroin to polymer mesh scaffold in the mixed solution of Example 10 being only 0.5:1, when the ratio of the two in Example 11 is increased to 1:1, the cell survival rate of 100% extract increases slightly, the pore size of the hydrogel in the cartilage repair scaffold decreases slightly, and the porosity decreases significantly. When the ratio increases to 1.5:1, the cell survival rate of 100% extract increases from 96.1% (Example 10) to 98.7% (Example 1), and the pore size and porosity of the hydrogel in the cartilage repair scaffold also decrease significantly. Continuing to increase the mass concentration of silk fibroin in the mixed solution, the cell survival rate of 100% extract continues to increase but the rate of increase slows down, and the pore size and porosity of the hydrogel continue to decrease. It can be seen from Example 1 and Examples 10-14 that increasing the proportion of silk fibroin in the mixed solution can reduce the cytotoxicity of the cartilage repair scaffold, which is beneficial to improving the biocompatibility of the cartilage repair scaffold, and is beneficial to reducing the pore size and porosity of the hydrogel in the cartilage repair scaffold, which is beneficial to promoting the hydrogel to be more fully filled in the fine gaps of the polymer mesh scaffold.

[0157] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A cartilage repair scaffold, characterized in that: The cartilage repair scaffold comprises a polymer mesh scaffold, the gaps of the polymer mesh scaffold are filled with hydrogel, liposome microspheres are dispersed in the hydrogel, wherein the compression modulus of the polymer mesh scaffold is 7.5-9.5 MPa; The raw materials of the hydrogel include a first degradable material and a cross-linking agent; wherein the first degradable material is silk fibroin, and the cross-linking agent is diglycidyl ether; the raw materials of the liposome microspheres include dimyristoyl phosphatidylcholine and / or hydrogenated soybean phosphatidylcholine; The mass ratio of the hydrogel to the liposome microspheres is 1:0.4-0.8, and the mass ratio of the hydrogel to the polymer mesh scaffold is 2-1:

1.

2. The cartilage repair scaffold according to claim 1, characterized in that: The polymer mesh stent is prepared from polymer monofilaments, the raw materials of which are lactide and trimethylene carbonate copolymers, and the molar ratio of the lactide to the trimethylene carbonate is 2-4:

1.

3. The cartilage repair scaffold according to claim 1, characterized in that: The hydrogel is loaded with a first drug, and the first drug includes at least one of chondroitin sulfate, diclofenac sodium, and glucosamine.

4. The cartilage repair scaffold according to claim 1, characterized in that: The liposome microspheres are loaded with a second drug, which includes at least one of chondroitin sulfate, diclofenac sodium, glucosamine, and sodium hyaluronate.

5. The cartilage repair scaffold according to claim 1, characterized in that: The particle size of the liposome microspheres is 50-100 nm.

6. The cartilage repair scaffold according to any one of claims 1 to 5, characterized in that: The height of the cartilage repair scaffold is 1-2 cm; and / or, the porosity of the hydrogel in the cartilage repair scaffold is 20-50%; and / or, the pore size of the hydrogel in the cartilage repair scaffold is 10-30 μm; And / or, the compression modulus of the cartilage repair scaffold is 7.5-9.5 MPa.

7. A method for preparing a cartilage repair scaffold according to any one of claims 1 to 6, characterized in that: The preparation method comprises the following steps: Step S1, dispersing silk fibroin in water to obtain a silk fibroin solution, and mixing the silk fibroin solution, a cross-linking agent and liposome microspheres to obtain a mixed solution; Step S2, providing a polymer mesh stent, immersing the polymer mesh stent in the mixed solution, and subjecting the mixed solution to a cross-linking reaction to obtain a composite stent; Step S3: freeze-drying and sterilizing the composite scaffold in sequence to obtain the cartilage repair scaffold.

8. The preparation method according to claim 7, characterized in that: The step S1 comprises: the mass concentration of the silk fibroin solution is 8-12%; and / or, dissolving liposomes in water to obtain the liposome microspheres, wherein the raw materials of the liposomes include dimyristoylphosphatidylcholine and / or hydrogenated soybean phosphatidylcholine; And / or, the particle size of the liposome microspheres is 50-100 nm; and / or, the cross-linking agent is diglycidyl ether; And / or, the mass ratio of the silk fibroin to the liposome microspheres is 1:0.4-0.

8.

9. The preparation method according to claim 7, characterized in that: In the step S2, the polymer mesh stent is woven from polymer monofilaments; the polymer monofilaments are copolymerized from lactide and trimethylene carbonate; And / or, the temperature of the cross-linking reaction is -20 to -10°C, and the time of the cross-linking reaction is 18 to 36 hours; And / or, the mass ratio of the silk fibroin to the polymer mesh scaffold is 2-1:

1.

10. The preparation method according to claim 7, characterized in that: The step S3 includes: the sterilization treatment method is Co 60 sterilization.

Citation Information

Patent Citations

  • High-strength hydrogel based on three-dimensional network support and preparation method of high-strength hydrogel

    CN108525018A

  • Self-renewal hydrated lubricating drug-loaded hydrogel microspheres, preparation method and application thereof

    CN113995891A

  • Hydrogel-porous zinc bidirectional scaffold and application thereof

    CN117045857A

  • Method for compounding aquo-gel to porous tissue engineering rack

    CN1586636A

  • Cell aggregate-hydrogel-polymer scaffold complex for cartilage regeneration, method for the preparation thereof and composition comprising the same

    US20100120149A1